GlassScriptPhysician profile
Michael D Beckman
NPI 1982191722
$1,411.54
in general payments reported to CMS, 2019-2025
11 companies · $83.45 in 2025
The $83.45 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $332 · 2023: $681 · 2024: $175 · 2025: $83.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775 · Travel and Lodging: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.20 |
| Travel and Lodging | $164.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $446.23 | 2023-2025 | Sprint Pns System |
| Merz Pharmaceuticals, LLC | $229.78 | 2021-2022 | |
| International Rehabilitative Sciences, INC | $168.70 | 2023-2024 | Rs 4i Plus Sequential Stimulator |
| Abbott Laboratories | $141.05 | 2023-2024 | Eterna, Proclaim |
| Nalu Medical, INC. | $115.59 | 2022-2023 | Nalu Neurostimulation System |
| Abbvie INC. | $107.66 | 2022 | |
| Collegium Pharmaceutical, INC. | $78.00 | 2023 | Belbuca, Xtampza |
| Teva Pharmaceuticals USA, INC. | $57.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.97 | 2021 | |
| Hikma Pharmaceuticals USA | $22.00 | 2022 | |
| Electronic Waveform Lab, INC. | $20.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Beckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.